Editas Medicine
EDIT
225 hedge funds and large institutions have $609M invested in Editas Medicine in 2023 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 53 increasing their positions, 74 reducing their positions, and 34 closing their positions.
40% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $9.68M
27% more capital invested
Capital invested by funds: $481M → $609M (+$128M)
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
2% more funds holding
Funds holding: 220 → 225 (+5)
1.21% less ownership
Funds ownership: 74.77% → 73.56% (-1.2%)
28% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.5M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.06M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.07M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$4.88M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$20.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$14.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$9.51M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.16M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.93M |
EDIT Hedge Fund Activity: Q4 2023 in Review
225 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2023, worth a combined $609M — up 27% from $481M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new EDIT positions and 34 closed out — a net gain of 5 holders — while 53 added to existing stakes and 74 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.5M. The largest seller was Woodline Partners, cutting an estimated $20.8M.
- 225 institutional investors held Editas Medicine (EDIT) as of Q4 2023, up from 220 in Q3 2023.
- Funds reported $609M of Editas Medicine stock for Q4 2023, up 27% quarter-over-quarter.
- 39 funds opened new Editas Medicine positions in Q4 2023 and 34 closed out, a net change of +5 holders.
- The largest Editas Medicine buyer in Q4 2023 was Morgan Stanley, an estimated $10.5M added.
- The largest Editas Medicine seller in Q4 2023 was Woodline Partners, an estimated $20.8M sold.
Based on aggregated 13F filings for Q4 2023.